Cambrex

East Rutherford, United States Founded: 1981 • Age: 45 yrs Acquired By Permira
CDMO of complex small molecule APIs, including highly potent APIs
Annual revenue $532.1M Latest available
Total funding - Funding intelligence
Employees 46 Tracked headcount
Investors 1 Known backers
Products 3 Services tracked
Competitors 10 Brand Intelligence

About Cambrex

Cambrex is a company based in East Rutherford (United States) founded in 1981 was acquired by Permira in August 2019. The company has 46 employees as of December 31, 2022. Cambrex has completed 7 acquisitions, including Avista Pharma, Biocatalysis and Halo Pharma. Cambrex offers products and services including Custom API Development, Analytical Testing, and Formulation Development. Cambrex operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.

  • Headquarter East Rutherford, United States
  • Employees 46 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cambrex Corporation
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $532.09 M (USD)
    0
    as on Dec 31, 2018
  • Net Profit
    $92.42 M (USD)
    -10
    as on Dec 31, 2018
  • EBITDA
    $101.5 M (USD)
    -30
    as on Dec 31, 2018
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    46

    as on Dec 31, 2022

  • Investments & Acquisitions
  • Acquired by
    Permira

    (Aug 07, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cambrex

Cambrex offers a comprehensive portfolio of products and services, including Custom API Development, Analytical Testing, and Formulation Development.

Product name locked
Category locked
Primary

Offers custom development and manufacturing of pharmaceutical APIs for clinical trials.

Product name locked
Category locked
Locked

Provides comprehensive analytical testing for drug stability and impurity identification.

Product name locked
Category locked
Locked

Supports early-phase formulation and clinical trial manufacturing processes.

People of Cambrex

Headcount 1000-5000
Employee Profiles 139
Employee Profiles
People
Dorothy Donnelly-brienza
Senior Vice President and Chief Human Resources Officer
People
Samantha M. Hanley
Vice President, General Counsel and Secretary
People
Robert Green
EVP and CFO
People
Thomas Loewald
CEO & Board Member

Unlock access to complete

Funding Insights of Cambrex

Premium access

Detailed funding history for Cambrex

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Cambrex

Cambrex has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Permira.

All
Venture Fund
Investor Description Founded Year Domain Location
Investments are made in technology, consumer, healthcare, and service sectors.
Locked Locked Locked
Premium access

Investor details for Cambrex

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cambrex

Cambrex has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Avista Pharma, Biocatalysis and Halo Pharma.

Investments
Premium access

Investment portfolio details for Cambrex

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Drug development, manufacturing, and testing services are provided to clients.
Locked Locked 2015 Locked
Drug discovery and development service provider
Locked Locked 2014 Locked
Stability storage services for pharmaceuticals and medical devices are provided.
Locked Locked 2012 Locked
Premium access

Complete acquisition details for Cambrex

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Cambrex

Premium access

Detailed financials for Cambrex

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cambrex Comparisons

Cambrex Primary company
Description
CDMO of complex small molecule APIs, including highly potent...
Location
East Rutherford, United States
Founded Year
1981
Annual Revenue
$532.09 M (USD)
Net Profit
$92.42 M (USD)
EBITDA
$101.5 M (USD)
Employees
46
As of 2022
Premium access

Peer comparison for Cambrex

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cambrex

Cambrex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Pharmaceutical and biotechnology company
Locked Locked Locked
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
Locked Locked Locked
APIs and drug products are developed and valorized in pharmaceuticals.
Locked Locked Locked
APIs, intermediates, and biochemical reagents are developed and manufactured.
Locked Locked Locked
APIs are developed and manufactured for therapeutic areas.
Locked Locked Locked
Contract development, manufacturing, and analytical services for APIs are offered.
Premium access

Detailed competitors of Cambrex

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cambrex

Premium access

Complete news archive for Cambrex

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cambrex

Cambrex was founded in 1981.

Cambrex is headquartered in East Rutherford, United States. It is registered at East Rutherford, New Jersey, United States.

As of Dec 31, 2022, the latest employee count at Cambrex is 46.

Annual revenue of Cambrex is $532.09M as on Dec 31, 2018.

Cambrex Corporation provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. They offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Their custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. Cambrex also develops processes to manufacture drug substances for clients use in toxicology studies, clinical studies and commercial supply. Their range of services include route selection, process and analytical development, process optimization and scale-up, safety assessments and product formulation.

Cambrex's top competitors include Laurus Labs, Symbiotec and NGL Fine Chem.

Cambrex offers Custom API Development, Analytical Testing, and Formulation Development.

Cambrex has made 7 acquisitions, including Avista Pharma, Biocatalysis, and Halo Pharma.

Cambrex has 1 investor. Key investors include Permira.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available